Pre-exposure prophylaxis access in federally qualified health centers across 11 United States metropolitan statistical areas

Abstract

Pre-exposure prophylaxis (PrEP) is a promising tool for HIV prevention, but uptake has been slow in key demographics and geographic areas including racial and ethnic minorities. Federally qualified health centers (FQHCs), serving those with heightened risk of contracting HIV, including low-income and minority patients regardless of ability to pay, are potential sites for PrEP delivery. This study aims to determine availability of PrEP at FQHCs in the US. FQHCs in the 11 largest U.S. metropolitan statistical areas (MSAs) were included. The south included Atlanta, Dallas, District of Columbia, Houston, and Miami. Reference MSAs included Boston, Chicago, Los Angeles, New York, Philadelphia, and San Francisco. We randomly selected 360 FQHCs for phone calls in which investigators queried the availability of PrEP for HIV prevention at each center. The study was powered to determine a 10% difference in proportion of clinics with PrEP services by region. We used a bivariate logistic regression to compare cities and regions. The percentage of FQHCs providing PrEP generally was low within this sample, with 0–28.0% offering PrEP services in the southern and 14.0–33.3% in reference metropolitan areas. Overall, 19.3% of clinics sampled indicated that they offered PrEP. Logistic regression did not show any difference between southern and reference regions (p = 0.779). However, the total number of FQHCs was significantly lower in southern metropolitan areas (p = 0.014). FQHCs in all metropolitan areas provided limited access to PrEP. Interventions, including technical assistance to increase PrEP availability in these settings catering to underserved populations, could be beneficial.

Keywords

Pre-exposure prophylaxis HIV prevention federally qualified health centers men who have sex with men public health

Get full access to this article

View all access options for this article.

References

Grant

Lama

Anderson

, et al. Preexposure chemoprophylaxis for HIV prevention in men who have sex with men. N Engl J Med 2010; 363: 2587–2599.

McCormack

Dunn

Desai

, et al. Pre-exposure prophylaxis to prevent the acquisition of HIV-1 infection (PROUD): effectiveness results from the pilot phase of a pragmatic open-label randomised trial. Lancet 2016; 387: 53–60.

Lieb

Prejean

Thompson

, et al. HIV prevalence rates among men who have sex with men in the southern United States: population-based estimates by race/ethnicity. AIDS Behav 2011; 15: 596–606.

Adimora

Fullilove

RE.

Men who have sex with men and women: pieces of the US HIV epidemic puzzle. LWW. Sex Trans Dis 2006 Oct: 33(10): 596–8.

Zablotska

Prestage

Holt

, et al. Australian gay men who have taken nonoccupational postexposure prophylaxis for HIV are in need of effective HIV prevention methods. J Acquir Immune Defic Syndr 2011; 58: 424–428.

Doblecki-Lewis

Liu

Feaster

, et al. Healthcare access and PrEP continuation in San Francisco and Miami following the US PrEP demo project. J Acquir Immune Defic Syndr (1999) 2017; 74: 531.

Liu

Kittredge

Vittinghoff

, et al. Limited knowledge and use of HIV post-and pre-exposure prophylaxis among gay and bisexual men. J Acquir Immune Defic Syndr 2008; 47: 241–247.

Escudero

Kerr

Wood

, et al. Acceptability of HIV pre-exposure prophylaxis (PrEP) among people who inject drugs (PWID) in a Canadian Setting. AIDS Behav 2015; 19: 752–757.

Cahill

Mayer

Boswell

SL.

The Ryan White HIV/AIDS program in the age of health care reform. Am J Public Health 2015; 105: 1078–1085.

10.

Doblecki-Lewis

Jones

Community federally qualified health centers as homes for HIV preexposure prophylaxis: perspectives from South Florida. J Int Assoc Provid AIDS Care 2016; 15: 522–528.

11.

Resneck

JSJ

Lipton

Pletcher

MJ.

Short wait times for patients seeking cosmetic botulinum toxin appointments with dermatologists. J Am Acad Dermatol 2007; 57: 985–989.

12.

Tsang

Resneck

Jr.

Even patients with changing moles face long dermatology appointment wait-times: a study of simulated patient calls to dermatologists. J Am Acad Dermatol 2006; 55: 54–58.

13.

HIV Surveillance Report. Centers for Disease and Prevention. HIV Surveillance Report, 2017; vol 29. http://www.cdc.gov/hiv/library/reports/hiv-surveillance.html (accessed 24 May 2019).

14.

Rusie

Orengo

Burrell

, et al. Preexposure prophylaxis initiation and retention in care over 5 years, 2012–2017: are quarterly visits too much? Clin Infect Dis 2017; 67: 283–287.

15.

Shover

Javanbakht

Shoptaw

, et al. HIV preexposure prophylaxis initiation at a large community clinic: differences between eligibility, awareness, and uptake. Am J Public Health 2018; 108: 1408–1417.

16.

Weiss K, Bratcher A, Sullivan P, et al. Geographic Access to PrEP Clinics among US MSM: Documenting PrEP Deserts. In Conference on retroviruses and opportunistic infections, Boston, Massachusetts, 2018..